Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1.

Cui T, Schally AV.

Oncotarget. 2018 Jun 19;9(47):28745-28756. doi: 10.18632/oncotarget.25676. eCollection 2018 Jun 19.

2.

Expression of hypothalamic neurohormones and their receptors in the human eye.

Dubovy SR, Fernandez MP, Echegaray JJ, Block NL, Unoki N, Perez R, Vidaurre I, Lee RK, Nadji M, Schally AV.

Oncotarget. 2017 Jun 3;8(40):66796-66814. doi: 10.18632/oncotarget.18358. eCollection 2017 Sep 15.

3.

Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.

Wu HM, Huang HY, Schally AV, Chao A, Chou HH, Leung PC, Wang HS.

Oncotarget. 2017 Jan 17;8(3):4410-4421. doi: 10.18632/oncotarget.13877.

4.

Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways.

Cui T, Jimenez JJ, Block NL, Badiavas EV, Rodriguez-Menocal L, Vila Granda A, Cai R, Sha W, Zarandi M, Perez R, Schally AV.

Oncotarget. 2016 Aug 16;7(33):52661-52672. doi: 10.18632/oncotarget.11024.

5.

Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.

Muñoz-Moreno L, Arenas MI, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM.

Oncotarget. 2016 Aug 9;7(32):52195-52206. doi: 10.18632/oncotarget.10710.

6.

New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor.

Kanashiro-Takeuchi RM, Szalontay L, Schally AV, Takeuchi LM, Popovics P, Jaszberenyi M, Vidaurre I, Zarandi M, Cai RZ, Block NL, Hare JM, Rick FG.

Oncotarget. 2015;6(12):9728-39.

8.

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.

Treszl A, Steiber Z, Schally AV, Block NL, Dezso B, Olah G, Rozsa B, Fodor K, Buglyo A, Gardi J, Berta A, Halmos G.

Oncotarget. 2013 Oct;4(10):1721-8.

9.

Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.

Szepeshazi K, Schally AV, Block NL, Halmos G, Nadji M, Szalontay L, Vidaurre I, Abi-Chaker A, Rick FG.

Oncotarget. 2013 May;4(5):751-60.

10.

Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

Jaszberenyi M, Schally AV, Block NL, Nadji M, Vidaurre I, Szalontay L, Rick FG.

Oncotarget. 2013 Mar;4(3):422-32.

11.

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.

Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG.

Oncotarget. 2012 Sep;3(9):988-97.

12.

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].

Szepeshazi K, Schally AV, Keller G, Block NL, Benten D, Halmos G, Szalontay L, Vidaurre I, Jaszberenyi M, Rick FG.

Oncotarget. 2012 Jul;3(7):686-99.

Supplemental Content

Loading ...
Support Center